JAK/STAT Signaling: From Mechanisms to Emerging Therapeutics

Introduction:: The JAK/STAT pathway controls various important cell processes, and alterations in this pathway, driven by genetic changes, inflammatory triggers, and viral interference, can lead to autoimmune diseases, cancers, and chronic inflammatory conditions. Methods:: This article is based on the current literature regarding the Molecular Mechanism, Physiological Functions, and Pathological Implications of the JAK/STAT Signaling Pathway. Emphasis has been given to those research works that discuss Regulatory Feedback, Cross-talk, and Therapeutic Interventions of the JAK/STAT Pathway. Results:: The analysis highlighted the intricate regulatory characteristics associated with JAK/STAT signaling, including the role of feedback inhibitors SOCS and PIAS proteins, as well as crosstalk with other signaling pathways that activate MAPK or PI3K/Akt pathways. Significant therapeutic advances have been made with the development of FDA-approved JAK inhibitors and experimental STAT-targeting candidates with therapeutic potential in various clinical contexts, including cancer immunotherapy and treatment of hyperinflammatory syndromes associated with COVID-19. Discussion:: Although JAK/STAT inhibitors have proven significant health benefits, challenges associated with resistance, off-target activities, and selectivity remain. Improving these targets may boost the outcome of therapy. Conclusion:: The JAK/STAT pathway is an important target in the management of disease, and the knowledge of its regulatory mechanisms has provided particularly interesting insights.